Fundamental Analysis of Indian Pharmaceutical Companies PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Fundamental Analysis of Indian Pharmaceutical Companies PDF full book. Access full book title Fundamental Analysis of Indian Pharmaceutical Companies by CMA(Dr.) Ashok Panigrahi. Download full books in PDF and EPUB format.
Author: CMA(Dr.) Ashok Panigrahi Publisher: ISBN: Category : Languages : en Pages : 24
Book Description
Estimation of real worth of a stock is made by considering the earning potential of the company which depends on investment environment and factors relating to specific industry, competitiveness, quality of management, operational efficiency, profitability, capital structure and dividend policy. For investing in a company many people use fundamental analysis for the selection and technical analysis to make their buy and sell decisions. It relates to the examination of the intrinsic worth of a company to find out whether the current market price is fair or not, whether it is overpriced or underpriced. It is believed that analyzing the economy, strategy, management, product, financial status and other related information will help to choose shares that will outperform the market and provide consistent gains to the investor. It is the examination of the underlying forces that affect the interest of the economy, industrial sectors and companies. Here an attempt has been made to analyze the fundamental analysis through analyzing the financial performance of ten selected Pharma and Healthcare companies by using various statistical techniques. Torrent Pharmaceuticals stands as No. 1 company followed by Piramal which stood as the second.
Author: CMA(Dr.) Ashok Panigrahi Publisher: ISBN: Category : Languages : en Pages : 24
Book Description
Estimation of real worth of a stock is made by considering the earning potential of the company which depends on investment environment and factors relating to specific industry, competitiveness, quality of management, operational efficiency, profitability, capital structure and dividend policy. For investing in a company many people use fundamental analysis for the selection and technical analysis to make their buy and sell decisions. It relates to the examination of the intrinsic worth of a company to find out whether the current market price is fair or not, whether it is overpriced or underpriced. It is believed that analyzing the economy, strategy, management, product, financial status and other related information will help to choose shares that will outperform the market and provide consistent gains to the investor. It is the examination of the underlying forces that affect the interest of the economy, industrial sectors and companies. Here an attempt has been made to analyze the fundamental analysis through analyzing the financial performance of ten selected Pharma and Healthcare companies by using various statistical techniques. Torrent Pharmaceuticals stands as No. 1 company followed by Piramal which stood as the second.
Author: Ritika Goel Publisher: ISBN: Category : Languages : en Pages : 21
Book Description
“Risk comes from not knowing what you're doing.” These simple yet powerful words by the legendary investor Warren Buffett are the main driving forces of this paper. Investing is by no means a simple process and this paper is a step to help anyone associated with and having knowledge of stock market investments to climb the first ladder towards a brighter investment future. The paper focuses on fundamental analysis of 17 global level competing pharmaceutical companies. The main classification used to categorize the companies was the type of drugs they make i.e., branded, generic and oncogenic. Within this broad classification, the companies have been chosen on the basis of their leading revenue numbers. The paper considers 14 important fundamental ratios that help determine which stock is moving high in the market, in the concerned industry, based on both macroeconomic and microeconomic factors. These ratios can also be used to calculate investment prospects for other sectors.
Author: Mainak Mazumdar Publisher: Springer Science & Business Media ISBN: 3790828750 Category : Business & Economics Languages : en Pages : 215
Book Description
This book explains how government support and institutional set up facilitated the evolution of the Indian pharmaceutical industry and provides an economic analysis of firm strategies due to recent policy changes. The book is useful for researchers interested in understanding the transition of a lifeline sector for an emerging economy like India. Students of public policy, health administrators and health economists who are interested in the functioning of the pharmaceutical sector that produces life saving drugs in developing nations will find this book useful. The book also provides good coverage on data envelopment analysis (DEA), a useful technique for understanding productivity and efficiency. It can provide guidance to the research students on the applicability of DEA technique to address various research questions for analysis. The book will be a valuable addition to libraries in colleges of pharmacy and medicine as well as to all other academic and research centers.
Author: Yaeko Mitsumori Publisher: Springer ISBN: 9811067902 Category : Business & Economics Languages : en Pages : 122
Book Description
This study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d‘) inserted in the Patent Act 2005 might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents. The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India’s very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis’ Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing.
Author: Tamal Datta Chaudhuri Publisher: ISBN: Category : Languages : en Pages : 23
Book Description
When the Indian economy shifted from a process patent regime to a product patent regime in 2005, there was a thought as to whether Indian pharma companies would be able to weather the change in the regime. However, they have indeed succeeded in this transition and have grown in size. The world pharma majors' confidence in Indian manufacturers has increased and the growth of the domestic pharmaceutical industry has outperformed the growth of the global pharmaceutical industry. The purpose of this paper is to explore the change in market perception about Indian pharma companies in the background of their fundamental performance and their growth prospects. We focus on the PE multiples of Indian pharma companies and their determinants. The study is relevant in today's market context where there are signs of a global slowdown and which has affected stock markets across the world, including the Indian stock market.
Author: CMA(Dr.) Ashok Panigrahi Publisher: ISBN: Category : Languages : en Pages : 0
Book Description
Financial performance is a subjective measure of how well a firm can use assets from its primary mode of business and generate revenues. This term is also used as a general measure of a firm's overall financial health over a given period of time, and can be used to compare similar firms across the same companies or to compare companies or sectors in aggregation. A firm's performance measurement has been the subject matter of discussion for decision makers as managers, planners, economists and academic staff since long many years. Financial analysts often assess firm's production and productivity performance, profitability performance, liquidity performance, leverage performance, asset utilisation performance and growth performance. The financial performance analysis identifies the financial strengths and weaknesses of the firm by properly establishing relationships between the items of the balance sheet and profit and loss account. In this context researcher has undertaken an analysis of financial performance of pharmaceutical companies to understand how management of finance plays a crucial role in the growth. In this paper an attempt has been made to analyse the profitability position of five leading pharmaceutical companies of India with the help of mean, standard deviation, co-efficient of variation, multiple regression, and analysis of variance. The increase in profitability will not only yield greater efficiency but also improve financial performance in future. The study is conducted by taking into account of the data for five years from 2011-2012 to 2015-2016. The Pharmaceutical companies selected for study are Lupin, Wochkardt, Glenmark, Abott and Torrent. The financial performance of these companies are evaluated and found that the profitability of the selected pharmaceutical companies in India during the study period is satisfactory.
Author: Mithun Nandy Publisher: ISBN: 9789811669224 Category : Languages : en Pages : 0
Book Description
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the 'Pharmacy of the World' and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as 'Innovate in India and Serve to the World'. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach. Dr. Mithun Nandy has over 16 years of pharmaceutical industry experience and is currently designated as Assistant General Sales Manager in Hegde & Hegde Pharmaceutica LLP, Mumbai, India. He is responsible for the different domestic and international market operations at H&H which are connected to pharmaceutical product promotion and selling. He has presented numerous research papers and posters at different national and international management conferences. He has a good number of empirical research papers published in various reputable peer-reviewed international journals. His professional success story has been featured in IQVIA Sales View. .
Author: Gerhard Schroeck Publisher: John Wiley & Sons ISBN: 0471429740 Category : Business & Economics Languages : en Pages : 354
Book Description
An analysis of the links between risk management and value creation Risk Management and Value Creation in Financial Institutions explores a variety of methods that can be utilized to create economic value at financial institutions. This invaluable resource shows how banks can use risk management to create value for shareholders, addresses the advantages of risk-adjusted return on capital (RAROC) measures, and develops the foundations for a model to identify comparative advantages that emerge as a result of risk-management decisions. It is the only book needed for banking executives interested in the relationship between risk management and value creation.
Author: Kung-Chung Liu Publisher: Springer Nature ISBN: 981138102X Category : Law Languages : en Pages : 513
Book Description
This open access book analyses intellectual property codification and innovation governance in the development of six key industries in India and China. These industries are reflective of the innovation and economic development of the two economies, or of vital importance to them: the IT Industry; the film industry; the pharmaceutical industry; plant varieties and food security; the automobile industry; and peer production and the sharing economy. The analysis extends beyond the domain of IP law, and includes economics and policy analysis. The overarching concern that cuts through all chapters is an inquiry into why certain industries have developed in one country and not in the other, including: the role that state innovation policy and/or IP policy played in such development; the nature of the state innovation policy/IP policy; and whether such policy has been causal, facilitating, crippling, co-relational, or simply irrelevant. The book asks what India and China can learn from each other, and whether there is any possibility of synergy. The book provides a real-life understanding of how IP laws interact with innovation and economic development in the six selected economic sectors in China and India. The reader can also draw lessons from the success or failure of these sectors.
Author: CMA(Dr.) Ashok Panigrahi
Author: CMA(Dr.) Ashok Panigrahi
Author: Ritika Goel
Author: Mainak Mazumdar
Author: Yaeko Mitsumori
Author: Tamal Datta Chaudhuri
Author: CMA(Dr.) Ashok Panigrahi
Author: Poorti Srivastava Marino
Author: Mithun Nandy
Author: Gerhard Schroeck
Author: Kung-Chung Liu